HOME >> BIOLOGY >> NEWS
BRCA mutations not associated with colorectal cancer risk, studies suggest

Two studies in the January 7 issue of the Journal of the National Cancer Institute suggest that mutations in the genes BRCA1 and BRCA2 are not associated with an increased risk of colorectal cancer.

Mutations in BRCA1 and BRCA2, which are present in about 2.5% of the Ashkenazi Jewish population, have been associated with an increased risk of breast and ovarian cancer, but it is unclear whether these mutations also increase the risk of colorectal cancer. Some studies have suggested an increased risk of colorectal cancer among mutation carriers, whereas other studies have found no such association. Current nationally recognized guidelines recommend that all BRCA1/2 mutation carriers be informed that they may be at an increased risk for colorectal cancer.

Tomas Kirchhoff, Ph.D., Kenneth Offit, M.D., and their colleagues at the Memorial Sloan-Kettering Cancer Center in New York compared the incidence of BRCA1/2 mutations in 586 Ashkenazi Jewish patients with colorectal cancer with that of 5,012 patients without a known history of colorectal cancer. The authors found no association between the presence of a BRCA mutation and risk of colorectal cancer.

In a second study, Bethany L. Niell and Stephen B. Gruber, M.D., Ph.D., of the University of Michigan, Ann Arbor, and their colleagues performed genetic testing on 1,422 patients with colorectal cancer and 1,566 control subjects without colorectal cancer in a population-based study in Israel. They also found no association between the presence of a BRCA mutation and the risk of colorectal cancer.

A family history of breast cancer in a female relative was not associated with an increased risk of colorectal cancer, even after adjusting for the presence of a BRCA founder mutation. The authors conclude that Ashkenazi BRCA founder mutations do not confer a strongly elevated risk of colorectal cancer. Similarly, a family history of breast cancer does not appear to be a strong risk factor for
'"/>

Contact: Katherine Arnold
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jan-2004


Page: 1 2

Related biology news :

1. Genetic mutations linked to the practice of burning coal in homes in China
2. Rare mutations can significantly increase risk factor for heart disease
3. The mother lode of mutations
4. Mastectomy dramatically reduces breast cancer risk among women with BRCA1/2 mutations
5. Yeast mutations offer window into human disease
6. Ancient DNA mutations permitted humans to adapt to colder climates, UCI researchers find
7. BRCA mutations do not increase risk of colorectal cancer
8. Researchers describe novel gene mutations associated with Alzheimer disease
9. Major mutations, not many small changes, might lead way to new species
10. Genetics mutations resulting in delayed puberty are focus of MCG study
11. Gene mutations that cause hearing loss discovered

Post Your Comments:
(Date:2/5/2015)... 28, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... Global Online CEO Conference on January 29 th ... Pereira , CEO of NXT-ID will present and host ... Wocket smart wallet and its full suite of biometric ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the ... report to their offering. , The ... individual is who she/he is claiming to be, and for ... unique physical characteristics, such as fingerprint, hand or palm print, ...
Breaking Biology News(10 mins):CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
(Date:3/3/2015)... Experts and industry insiders from around the ... Alltech REBELation exploring innovation, inspiration and world-changing ideas in ... 31st year, Alltech’s annual international conference traditionally draws more ... to join the REBELation at an extra discount registration ... at which point the standard early registration rate will ...
(Date:3/3/2015)... 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: SQD), a life sciences ... products for advanced microarray diagnostics, today announced it ... its Management team. In his capacity as CFO ... from a development stage to a commercially successful ... Company,s capital market strategy and to secure funding ...
(Date:3/3/2015)... 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... development of and commercialization of regenerative cell therapies to ... today that it has received the final payment to ... Inc. (OTC Bulletin Board: AMBS ). ... the final payments due to Regenicin in the amount ...
(Date:3/3/2015)... ROCKVILLE, Md. , March 3, 2015  RegeneRx ... an editorial in the scientific journal, Expert Opinion ... and his colleague, Dr. Zhenggang Zhang , at ... reported that Thymosin beta 4 (TB4) has ... (PNS) remodeling 24 hours or more post-injury, leading to ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
Cached News: